OncoMatch/Clinical Trials/NCT04935684
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
Is NCT04935684 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Fecal Microbiota Transplantation for acute leukemia in remission.
Treatment: Fecal Microbiota Transplantation — The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications and particularly Graft versus Host Disease (GvHD). The hypothesis of this study is that allogeneic FMT may improve outcomes of these patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Multiple Myeloma
Chronic Lymphocytic Leukemia
Prior therapy
Must have received: stem cell transplant — myelo-ablative allogeneic
Patients undergoing a myelo-ablative allo-HSCT for a controlled haematologic malignant disease, with peripheral stem cells, whatever the type of donor (except cord blood)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify